The Resaphene Suisse AG has been informed after the oral proceedings at the European Patent Office about the upcoming patent grant. As the next step, the Board of Directors also expects the conclusion of the patent procedure in the USA.

In February 2019, the management will present the tinnitus therapy in the USA and push forward with the expansion there. A decision on whether to establish a local subsidiary or use distribution partners has not yet been made.